Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

1.38
Delayed Data
As of Feb 24
 0.00 / 0.00%
Today’s Change
1.16
Today|||52-Week Range
8.49
+9.52%
Year-to-Date
Better Buy: Novavax, Inc. vs. Inovio Pharmaceuticals
Feb 16 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close1.38
Today’s open1.40
Day’s range1.38 - 1.47
Volume5,821,066
Average volume (3 months)7,538,937
Market cap$374.3M
Dividend yield--
Data as of 3:59pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-75.05%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book1.27

Competitors

 Today’s
change
Today’s
% change
NKNantKwest Inc-0.17-3.60%
MRUSMerus NV+0.61+2.54%
PDLIPDL BioPharma Inc-0.02-0.89%
MCRBSeres Therapeutics I...-0.10-1.09%
Data as of 3:59pm ET, 02/24/2017

Financials

Next reporting dateMarch 13, 2017
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Chief Financial Officer, Treasurer &
Senior VP
Barclay A. Phillips
Corporate headquarters
Gaithersburg, Maryland

Forecasts


Search for Jobs